secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001213900-24-065378
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics Q2 net loss $9.5M; cash $89.6M; pipeline milestones on track
--------------------------------------------------------------------------------

- Net loss $9.5M ($0.45/share) vs $11.3M ($1.00/share) in Q2 2023; R&D expenses decreased to $6.4M.
- Cash and investments $89.6M at June 30, including $42M net from April private placement; funding expected into 2026.
- Expects preliminary data from 6-month evaluable patients in ADVANCED-2 trial (TARA-002 in NMIBC) in Q4 2024.
- Pivotal trial dosing for IV Choline Chloride in PN patients expected to begin Q1 2025 after FDA alignment.
- Appointed Lisa Schlesinger as VP, Head of New Product Development and Market Access in June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024065378/0001213900-24-065378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024065378/ea0210016-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-065378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer